Graft versus host disease (GVHD) is a serious complication that increases mortality and significantly impacts quality of life in allogeneic HCT recipients.  A thorough understanding of the various clinical manifestations of acute and chronic GVHD is essential for the early recognition of signs and symptoms. Oncology nurses require ongoing education that provides expert guidance necessary for the optimal management of patients with GVHD.

Graft versus host disease (GVHD) is a serious complication that increases mortality and significantly impacts quality of life in allogeneic HCT recipients.  A thorough understanding of the various clinical manifestations of acute and chronic GVHD is essential for the early recognition of signs and symptoms. Oncology nurses require ongoing education that provides expert guidance necessary for the optimal management of patients with GVHD.

Clinician education on the topic of integrative therapies can help patients be informed enough to make the best decisions regarding non-conventional and conventional therapies to optimize their oncologic outcomes and quality of life.

Both acute and chronic graft-versus-host disease, while fairly common in allogeneic HSCT, can be potentially fatal. The clinical manifestations of this complication can linger for years and often times impair quality of life drastically. Hematology and oncology specialists can optimize care by early recognition and prompt initiation of systemic therapies.

In order to improve smoking cessation efforts, health care providers need to understand options for smoking cessation therapy as well as the clinical data supporting these interventions. Pharmacists can play a critical role in patient education, therapy recommendations, and therapy management for smoking cessation.

The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy.

Both acute and chronic graft-versus-host disease, while fairly common in allogeneic HSCT, can be potentially fatal. The clinical manifestations of this complication can linger for years and often times impair quality of life drastically. Hematology and oncology specialists can optimize care by early recognition and prompt initiation of systemic therapies.

Although considerable progress has been made in identifying supportive care issues in HCT survivors, large, prospective trials demonstrating the effectiveness of supportive care interventions for HCT-related complications are needed to guide future development of evidence-based guidelines. Importantly, because long-term HCT recipients may no longer be followed by transplant centers, recommendations for supportive care should be geared toward community healthcare providers who may not routinely care for HCT recipients.

Management of pediatric patients with cancer is complex and requires multidisciplinary coordination to organize cancer treatment and supportive care during treatment. In addition, care coordination is essential during the survivorship and end-of-life phases of pediatric cancer treatment.